Digital Life Line, a stepdown subsidiary DISA (SGX:532) unit DiSa Digital Safety, received an approval for the clinical deployment of its Automated Visual Acuity Test device at a hospital ophthalmology clinic in Hong Kong.
Initially, the device went through a successful three-month trial deployment at a public ophthalmology clinic in Hong Kong, according to a filing with the Singapore Exchange on Wednesday.
The device is aimed at combating myopia, which affects more than 40% of school children in Hong Kong.
Shares of the company surged 100% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。